Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibody shot could shield against Tick-Borne brain virus

NCT ID NCT07377253

Prevention Sponsor: Giuseppe Pantaleo Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a lab-made antibody called TBE025 in 18 healthy adults aged 18 to 55. The goal is to see if it is safe and how the body processes it when given through a vein. Participants receive one dose and are closely monitored for side effects. This research helps determine the right dose for future studies aiming to prevent tick-borne encephalitis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 18 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 to \<55 years * Good general health (medical history, physical exam, normal labs) * Written informed consent provided * Ability to read and understand local language * Contraception requirements : Women of childbearing potential: negative pregnancy test, surgically sterile, postmenopausal, or using highly effective contraception for 3 months post-infusion. Men: surgically sterile or using highly effective contraception (self or partner) and abstain from sperm donation for 3 months post-infusion. Exclusion Criteria: * BMI \<19 or \>30 * Infections: HIV, active hepatitis B (HBsAg), active hepatitis C * Prior participation in investigational study within 30 days * History of hypersensitivity to monoclonal antibodies * Recent surgery or unresolved adverse events * Active autoimmune disease requiring systemic treatment * Recent use of immunosuppressive agents or immunoglobulins * Immunodeficiency diagnosis * Significant cardiovascular events within 6 months * Live/attenuated vaccines within 28 days * Major surgery within 28 days * Pregnancy or breastfeeding * Professional or private link with the research team * Any condition judged by the investigator to interfere with safety or study results

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for The tick-borne encephalitis virus (TBEV) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

tick-borne encephalitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

The tick-borne encephalitis virus (TBEV)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Universitaire Hospitalier Vaudois (CHUV)

    Lausanne, Canton of Vaud, 1011, Switzerland